

Paolo Bonanni

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8557906/publications.pdf>

Version: 2024-02-01

177
papers

4,412
citations

126901

33
h-index

161844

54
g-index

189
all docs

189
docs citations

189
times ranked

5046
citing authors

#	ARTICLE	IF	CITATIONS
1	Replacing vaccine paper package inserts: a multi-country questionnaire study on the acceptability of an electronic replacement in different target groups. BMC Public Health, 2022, 22, 156.	2.9	2
2	The New Quadrivalent Adjuvanted Influenza Vaccine for the Italian Elderly: A Health Technology Assessment. International Journal of Environmental Research and Public Health, 2022, 19, 4166.	2.6	11
3	Equity in vaccination policies to overcome social deprivation as a risk factor for invasive meningococcal disease. Expert Review of Vaccines, 2022, 21, 659-674.	4.4	14
4	Predictors of Influenza Vaccination Uptake and the Role of Health Literacy among Health and Social Care Volunteers in the Province of Prato (Italy). International Journal of Environmental Research and Public Health, 2022, 19, 6688.	2.6	3
5	Reasons for the Intention to Refuse COVID-19 Vaccination and Their Association with Preferred Sources of Information in a Nationwide, Population-Based Sample in Italy, before COVID-19 Vaccines Roll Out. Vaccines, 2022, 10, 913.	4.4	16
6	Electronic Package Leaflets for Vaccines: What Are People's Perceptions in Italy?. Vaccines, 2022, 10, 1075.	4.4	0
7	Knowledge of University Students in Health Care Settings on Vaccines and Vaccinations Strategies: Impact Evaluation of a Specific Educational Training Course during the COVID-19 Pandemic Period in Italy. Vaccines, 2022, 10, 1085.	4.4	4
8	A global agenda for older adult immunization in the COVID-19 era: A roadmap for action. Vaccine, 2021, 39, 5240-5250.	3.8	52
9	Universal and targeted varicella vaccination. Lancet Infectious Diseases, The, 2021, 21, 11-12.	9.1	5
10	Need to take special care of non-responders to hepatitis B vaccination among health-care workers, students and chronic patients. Human Vaccines and Immunotherapeutics, 2021, 17, 580-582.	3.3	2
11	Maintain and increase vaccination coverage in children, adolescents, adults and elderly people: Let's avoid adding epidemics to the pandemic. Vaccine, 2021, 39, 1187-1189.	3.8	28
12	The recommended lifetime immunization schedule from the board of vaccination calendar for life in Italy: A continuing example of impact on public health policies. Vaccine, 2021, 39, 1183-1186.	3.8	11
13	A Study of Varicella Seroprevalence in a Pediatric and Adolescent Population in Florence (Italy). Natural Infection and Vaccination-Acquired Immunization. Vaccines, 2021, 9, 152.	4.4	2
14	Travelers' Attitudes, Behaviors, and Practices on the Prevention of Infectious Diseases: A Study for Non-European Destinations. International Journal of Environmental Research and Public Health, 2021, 18, 3110.	2.6	6
15	Vaccine Production Process: How Much Does the General Population Know about This Topic? A Web-Based Survey. Vaccines, 2021, 9, 564.	4.4	4
16	Cost-effectiveness of childhood influenza vaccination in Europe: results from a systematic review. Expert Review of Pharmacoeconomics and Outcomes Research, 2021, 21, 911-922.	1.4	4
17	Health Communication in COVID-19 Era: Experiences from the Italian VaccinarSA Network Websites. International Journal of Environmental Research and Public Health, 2021, 18, 5642.	2.6	32
18	The Role of Serology Testing to Strengthen Vaccination Initiatives and Policies for COVID-19 in Europe. Covid, 2021, 1, 20-38.	1.5	22

#	ARTICLE	IF	CITATIONS
19	Factors Influencing SARS-CoV-2 Vaccine Acceptance and Hesitancy in a Population-Based Sample in Italy. <i>Vaccines</i> , 2021, 9, 633.	4.4	35
20	Immunization funding across 28 European countries. <i>Expert Review of Vaccines</i> , 2021, 20, 639-647.	4.4	4
21	Descriptive Observational Study of Tdap Vaccination Adhesion in Pregnant Women in the Florentine Area (Tuscany, Italy) in 2019 and 2020. <i>Vaccines</i> , 2021, 9, 955.	4.4	3
22	Coadministration of Anti-Viral Monoclonal Antibodies With Routine Pediatric Vaccines and Implications for Nirsevimab Use: A White Paper. <i>Frontiers in Immunology</i> , 2021, 12, 708939.	4.8	8
23	Fourteen yearsâ€™ clinical experience and the first million babies protected with human live-attenuated vaccine against rotavirus disease in Italy. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 4636-4645.	3.3	5
24	Quality and Safety of Vaccines Manufacturing: An Online Survey on Attitudes and Perceptions of Italian Internet Users. <i>Vaccines</i> , 2021, 9, 1015.	4.4	5
25	Human Papillomavirus Vaccines. , 2021, , 147-157.		0
26	Epidemiology and prevention of respiratory syncytial virus infections in children in Italy. <i>Italian Journal of Pediatrics</i> , 2021, 47, 198.	2.6	58
27	A Study of Hepatitis A Seroprevalence in a Paediatric and Adolescent Population of the Province of Florence (Italy) in the Period 2017â€“2018 Confirms Tuscany a Low Endemic Area. <i>Vaccines</i> , 2021, 9, 1194.	4.4	0
28	Six years of activity of the Italian vaccine portal "VaccinarSÃ¬": a web traffic evaluation using Google Analytics. <i>Annali Di Igiene: Medicina Preventiva E Di Comunita</i> , 2021, 33, 109-122.	0.7	4
29	The Role of Health Literacy in COVID-19 Preventive Behaviors and Infection Risk Perception: Evidence from a Population-Based Sample of Essential Frontline Workers during the Lockdown in the Province of Prato (Tuscany, Italy). <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 13386.	2.6	18
30	High chance to overcome the non-responder status to hepatitis B vaccine after a further full vaccination course: results from the extended study on healthcare students and workers in Florence, Italy. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 949-954.	3.3	10
31	The unmet need for pertussis prevention in patients with chronic obstructive pulmonary disease in the Italian context. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 340-348.	3.3	16
32	Co-administration of vaccines: a focus on tetravalent Measles-Mumps-Rubella-Varicella (MMRV) and meningococcal C conjugate vaccines. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 1313-1321.	3.3	12
33	Varicella vaccination in Italy and Germany â€“ different routes to success: a systematic review. <i>Expert Review of Vaccines</i> , 2020, 19, 843-869.	4.4	14
34	Increasing Measles Seroprevalence in a Sample of Pediatric and Adolescent Population of Tuscany (Italy): A Vaccination Campaign Success. <i>Vaccines</i> , 2020, 8, 512.	4.4	5
35	The Experience of VaccinarSinToscana Website and the Role of New Media in Promoting Vaccination. <i>Vaccines</i> , 2020, 8, 644.	4.4	15
36	Attitudes and Beliefs on Influenza Vaccination during the COVID-19 Pandemic: Results from a Representative Italian Survey. <i>Vaccines</i> , 2020, 8, 711.	4.4	83

#	ARTICLE	IF	CITATIONS
37	Strengthening the Evidence-Based Approach to Guiding Effective Influenza Vaccination Policies. <i>Vaccines</i> , 2020, 8, 342.	4.4	6
38	Fake News and Covid-19 in Italy: Results of a Quantitative Observational Study. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 5850.	2.6	98
39	SARS-CoV-2 Seroprevalence Survey in People Involved in Different Essential Activities during the General Lock-Down Phase in the Province of Prato (Tuscany, Italy). <i>Vaccines</i> , 2020, 8, 778.	4.4	23
40	The status of human papillomavirus vaccination recommendation, funding, and coverage in WHO Europe countries (2018–2019). <i>Expert Review of Vaccines</i> , 2020, 19, 1073-1083.	4.4	27
41	Why the Anti-Meningococcal B Vaccination during Adolescence Should Be Implemented in Italy: An Overview of Available Evidence. <i>Microorganisms</i> , 2020, 8, 1681.	3.6	4
42	Rubella Seroprevalence Boost in the Pediatric and Adolescent Population of Florence (Italy) as a Preventive Strategy for Congenital Rubella Syndrome (CRS). <i>Vaccines</i> , 2020, 8, 599.	4.4	3
43	Impact of Influenza Vaccination on All-Cause Mortality and Hospitalization for Pneumonia in Adults and the Elderly with Diabetes: A Meta-Analysis of Observational Studies. <i>Vaccines</i> , 2020, 8, 263.	4.4	30
44	COVID-19 in Italy: Considerations on official data. <i>International Journal of Infectious Diseases</i> , 2020, 98, 188-190.	3.3	30
45	Assessment of the Clinical and Economic Impact of Different Immunization Protocols of Measles, Mumps, Rubella and Varicella in Internationally Adopted Children. <i>Vaccines</i> , 2020, 8, 60.	4.4	4
46	Discrepancies Between Protocols of Immunization Targeting Internationally Adopted Children in Western Countries. <i>Vaccines</i> , 2020, 8, 75.	4.4	3
47	Utility of Healthcare System-Based Interventions in Improving the Uptake of Influenza Vaccination in Healthcare Workers at Long-Term Care Facilities: A Systematic Review. <i>Vaccines</i> , 2020, 8, 165.	4.4	11
48	Hepatitis B Seroprevalence in the Pediatric and Adolescent Population of Florence (Italy): An Update 27 Years after the Implementation of Universal Vaccination. <i>Vaccines</i> , 2020, 8, 156.	4.4	15
49	Paediatric activities and adherence to vaccinations during the COVID-19 epidemic period in Tuscany, Italy: a survey of paediatricians. <i>Journal of Preventive Medicine and Hygiene</i> , 2020, 61, E125-E129.	0.9	22
50	Immunization Status against Measles, Mumps, Rubella and Varicella in a Large Population of Internationally Adopted Children Referred to Meyer Children's University Hospital from 2009 to 2018. <i>Vaccines</i> , 2020, 8, 51.	4.4	6
51	Anti-meningococcal B vaccination in Italian adolescents: a cost-effective health opportunity. <i>European Journal of Public Health</i> , 2020, 30, .	0.3	0
52	Invasive meningococcal disease in Italy: from analysis of national data to an evidence-based vaccination strategy. <i>Journal of Preventive Medicine and Hygiene</i> , 2020, 61, E152-E161.	0.9	9
53	From epidemiology to public health decision making: analysis on IMD & vaccination strategy in Italy. <i>European Journal of Public Health</i> , 2020, 30, .	0.3	0
54	Childhood vaccination coverage in Europe: impact of different public health policies. <i>Expert Review of Vaccines</i> , 2019, 18, 693-701.	4.4	39

#	ARTICLE	IF	CITATIONS
55	Vaccines Safety in Children and in General Population: A Pharmacovigilance Study on Adverse Events Following Anti-Infective Vaccination in Italy. <i>Frontiers in Pharmacology</i> , 2019, 10, 948.	3.5	27
56	Appropriateness and preferential use of different seasonal influenza vaccines: A pilot study on the opinion of vaccinating physicians in Italy. <i>Vaccine</i> , 2019, 37, 915-918.	3.8	10
57	Economic burden of HPV9-related diseases: a real-world cost analysis from Italy. <i>European Journal of Health Economics</i> , 2019, 20, 829-840.	2.8	7
58	Adjuvanted influenza vaccine for the Italian elderly in the 2018/19 season: an updated health technology assessment. <i>European Journal of Public Health</i> , 2019, 29, 900-905.	0.3	10
59	Non-familial paid caregivers as potential flu carriers and cause of spread: the primary prevention of flu measured through their adhesion to flu vaccination campaignsâ€”A Florentine experience. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 2416-2422.	3.3	7
60	The impact of childhood varicella vaccination on the incidence of herpes zoster in the general population: modelling the effect of exogenous and endogenous varicella-zoster virus immunity boosting. <i>BMC Infectious Diseases</i> , 2019, 19, 126.	2.9	22
61	Assessing Vaccine Hesitancy among Healthcare Workers: A Cross-Sectional Study at an Italian Paediatric Hospital and the Development of a Healthcare Workerâ€™s Vaccination Compliance Index. <i>Vaccines</i> , 2019, 7, 201.	4.4	27
62	Impact assessment of an education course on vaccinations in a population of pregnant women: a pilot study. <i>Journal of Preventive Medicine and Hygiene</i> , 2019, 60, E5-E11.	0.9	11
63	Impact assessment of an educational course on vaccinations in a population of medical students. <i>Journal of Preventive Medicine and Hygiene</i> , 2019, 60, E171-E177.	0.9	4
64	Influenza vaccination 2014â€“2015: Results of a survey conducted among general practitioners in Italy. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 1342-1350.	3.3	18
65	Enlarged free childhood vaccination offer in Italy proposed to curb the rise in the growing anti-vaccine message. <i>Expert Review of Vaccines</i> , 2018, 17, 1-3.	4.4	12
66	Estimation of the individual residual risk of cervical cancer after vaccination with the nonavalent HPV vaccine. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 1800-1806.	3.3	9
67	Safety and perception: What are the greatest enemies of HPV vaccination programmes?. <i>Vaccine</i> , 2018, 36, 5424-5429.	3.8	22
68	Health literacy and vaccination: A systematic review. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 478-488.	3.3	166
69	The appropriateness of the use of influenza vaccines: Recommendations from the latest seasons in Italy. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 699-705.	3.3	28
70	Is hepatitis B vaccination performed at infant and adolescent age able to provide long-term immunological memory? An observational study on healthcare students and workers in Florence, Italy. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 450-455.	3.3	17
71	Focusing on the implementation of 21st century vaccines for adults. <i>Vaccine</i> , 2018, 36, 5358-5365.	3.8	26
72	Cervical cancer prevention: An Italian scenario between organised screening and human papillomaviruses vaccination. <i>European Journal of Cancer Care</i> , 2018, 27, e12905.	1.5	9

#	ARTICLE	IF	CITATIONS
73	Lessons from an online vaccine communication project. <i>Vaccine</i> , 2018, 36, 6509-6511.	3.8	20
74	Vaccination of 50+ adults to promote healthy ageing in Europe: The way forward. <i>Vaccine</i> , 2018, 36, 5819-5824.	3.8	15
75	A new meningococcal B vaccine for adolescents and adults: characteristics and methods of use. <i>Journal of Preventive Medicine and Hygiene</i> , 2018, 59, E257-E260.	0.9	5
76	Application of socio-economic-health deprivation index, analysis of mortality and influenza vaccination coverage in the elderly population of Tuscany. <i>Journal of Preventive Medicine and Hygiene</i> , 2018, 59, E18-E25.	0.9	4
77	Impact of vaccination programs against measles, varicella and meningococcus C in Italy and in Tuscany and public health policies in the last decades. <i>Journal of Preventive Medicine and Hygiene</i> , 2018, 59, E120-E127.	0.9	4
78	Do Tuscan people adhere to meningococcal C vaccination during an emergency campaign?. <i>Journal of Preventive Medicine and Hygiene</i> , 2018, 59, E187-E193.	0.9	4
79	Strategies and actions of multi-purpose health communication on vaccine preventable infectious diseases in order to increase vaccination coverage in the population: The ESCULAPIO project. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 369-375.	3.3	15
80	Incidence of herpes zoster and post-herpetic neuralgia in Italy: Results from a 3-years population-based study. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 399-404.	3.3	28
81	Parents' insights after pediatric hospitalization due to rotavirus gastroenteritis in Italy. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 2155-2159.	3.3	9
82	The "Fluad Case" in Italy: Could it have been dealt differently?. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 379-384.	3.3	27
83	Hospitalizations for pneumonia, invasive diseases and otitis in Tuscany (Italy), 2002-2014: Which was the impact of universal pneumococcal pediatric vaccination?. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 428-434.	3.3	7
84	Economic studies applied to vaccines against invasive diseases: An updated budget impact analysis of age-based pneumococcal vaccination strategies in the elderly in Italy. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 417-422.	3.3	6
85	Recommended vaccinations for asplenic and hyposplenic adult patients. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 359-368.	3.3	84
86	Prevention of Herpes Zoster and its complications: From clinical evidence to real life experience. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 391-398.	3.3	17
87	Clinical and economic impact of herpes zoster vaccination in elderly in Italy. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 405-411.	3.3	5
88	The 2016 Lifetime Immunization Schedule, approved by the Italian scientific societies: A new paradigm to promote vaccination at all ages. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 2531-2537.	3.3	17
89	Impact of <i>Haemophilus influenzae</i> type b conjugate vaccination on hospitalization for invasive disease in children fifteen years after its introduction in Italy. <i>Vaccine</i> , 2017, 35, 6297-6301.	3.8	8
90	Varicella vaccination - the global experience. <i>Expert Review of Vaccines</i> , 2017, 16, 833-843.	4.4	128

#	ARTICLE	IF	CITATIONS
91	Community-acquired pneumonia in adults: Highlighting missed opportunities for vaccination. European Journal of Internal Medicine, 2017, 37, 13-18.	2.2	21
92	Evaluating the costs and benefits of pneumococcal vaccination in adults. Expert Review of Vaccines, 2017, 16, 93-107.	4.4	16
93	Cost-effectiveness analysis of the nine-valent HPV vaccine in Italy. Cost Effectiveness and Resource Allocation, 2017, 15, 11.	1.5	32
94	The burden of hospitalization due to HPV infections in Tuscany, Central Italy. Public Health, 2016, 141, 194-197.	2.9	2
95	Recommended immunization schedules for adults: Clinical practice guidelines by the Escmid Vaccine Study Group (EVASG), European Geriatric Medicine Society (EUGMS) and the World Association for Infectious Diseases and Immunological Disorders (WAidid). Human Vaccines and Immunotherapeutics, 2016, 12, 1-18.	3.3	49
96	Effectiveness of HPV vaccination in women reaching screening age in Italy. Journal of Clinical Virology, 2016, 84, 74-81.	3.1	11
97	Vaccine strategies: Optimising outcomes. Vaccine, 2016, 34, 6691-6699.	3.8	95
98	Vaccine safety evaluation: Practical aspects in assessing benefits and risks. Vaccine, 2016, 34, 6672-6680.	3.8	86
99	Coverage, efficacy or dosing interval: which factor predominantly influences the impact of routine childhood vaccination for the prevention of varicella? A model-based study for Italy. BMC Public Health, 2016, 16, 1103.	2.9	26
100	Vaccinating Italian infants with a new multicomponent vaccine (Bexsero®) against meningococcal B disease: A cost-effectiveness analysis. Human Vaccines and Immunotherapeutics, 2016, 12, 2148-2161.	3.3	30
101	Pneumococcal serotype distribution in adults with invasive disease and in carrier children in Italy: Should we expect herd protection of adults through infants' vaccination?. Human Vaccines and Immunotherapeutics, 2016, 12, 344-350.	3.3	25
102	Development and preliminary data on the use of a mobile app specifically designed to increase community awareness of invasive pneumococcal disease and its prevention. Human Vaccines and Immunotherapeutics, 2016, 12, 1080-1084.	3.3	20
103	Use of the nonavalent HPV vaccine in individuals previously fully or partially vaccinated with bivalent or quadrivalent HPV vaccines. Vaccine, 2016, 34, 757-761.	3.8	31
104	An eHealth Project on Invasive Pneumococcal Disease: Comprehensive Evaluation of a Promotional Campaign. Journal of Medical Internet Research, 2016, 18, e316.	4.3	7
105	Preparing to introduce the varicella vaccine into the Italian immunisation programme: varicella-related hospitalisations in Tuscany, 2004-2012. Eurosurveillance, 2016, 21, .	7.0	16
106	The role of the general practitioner in the screening and clinical management of chronic viral hepatitis in six EU countries. Journal of Preventive Medicine and Hygiene, 2016, 57, E51-60.	0.9	5
107	An Overview of Quadrivalent Human Papillomavirus Vaccine Safety. Pediatric Infectious Disease Journal, 2015, 34, 983-991.	2.0	103
108	Vaccination of boys or catch-up of girls above 11 years of age with the HPV-16/18 AS04-adjuvanted vaccine: where is the greatest benefit for cervical cancer prevention in Italy?. BMC Infectious Diseases, 2015, 15, 377.	2.9	3

#	ARTICLE	IF	CITATIONS
109	The intangible benefits of vaccination “ what is the true economic value of vaccination?. Journal of Market Access & Health Policy, 2015, 3, 26964.	1.5	19
110	Beliefs and Opinions of Health Care Workers and Students Regarding Influenza and Influenza Vaccination in Tuscany, Central Italy. Vaccines, 2015, 3, 137-147.	4.4	31
111	Deaths after Flud flu vaccine and the epidemic of panic in Italy. BMJ, The, 2015, 350, h116-h116.	6.0	70
112	New Italian immunisation plan is built on scientific evidence: Carlo Signorelli and colleagues reply to news article by Michael Day. BMJ, The, 2015, 351, h6775.	6.0	11
113	Effectiveness of vaccination against varicella in children under 5 years in Puglia, Italy 2006–2012. Human Vaccines and Immunotherapeutics, 2015, 11, 214-219.	3.3	20
114	Impact of universal vaccination against varicella in Italy. Human Vaccines and Immunotherapeutics, 2015, 11, 63-71.	3.3	47
115	Pneumococcal vaccination: what have we learnt so far and what can we expect in the future?. European Journal of Clinical Microbiology and Infectious Diseases, 2015, 34, 19-31.	2.9	52
116	Human papilloma virus vaccination: impact and recommendations across the world. Therapeutic Advances in Vaccines, 2015, 3, 3-12.	2.7	52
117	Evaluation of the economic burden of Herpes Zoster (HZ) infection. Human Vaccines and Immunotherapeutics, 2015, 11, 245-262.	3.3	40
118	A retrospective analysis of hospital discharge records for S. pneumoniae diseases in the elderly population of Florence, Italy, 2010–2012. Human Vaccines and Immunotherapeutics, 2015, 11, 156-165.	3.3	8
119	The burden of disease of Herpes Zoster in Tuscany. Human Vaccines and Immunotherapeutics, 2015, 11, 185-191.	3.3	6
120	Human papillomavirus prevalence in paired urine and cervical samples in women invited for cervical cancer screening. Journal of Medical Virology, 2015, 87, 508-515.	5.0	19
121	Budget impact analysis of universal rotavirus vaccination in the Local Health Unit 11 Empoli, Tuscany, Italy. Journal of Preventive Medicine and Hygiene, 2015, 56, E66-71.	0.9	1
122	How can the results of Health Technology Assessment (HTA) evaluations applied to vaccinations be communicated to decision-makers and stakeholders? The ISPOR Rome Chapter Project. Journal of Preventive Medicine and Hygiene, 2015, 56, E150-4.	0.9	1
123	Monitoring the web to support vaccine coverage: results of two years of the portal VaccinarSI. Epidemiologia E Prevenzione, 2015, 39, 88-93.	1.1	29
124	Assessment of the effectiveness of the universal varicella vaccination program in Toscana (Italy), in the period 2010-2013. Epidemiologia E Prevenzione, 2015, 39, 119-23.	1.1	6
125	Vaccine coverage in Italy and assessment of the 2012-2014 National Immunization Prevention Plan. Epidemiologia E Prevenzione, 2015, 39, 146-58.	1.1	74
126	Impact of meningococcal C conjugate vaccination campaign in Emilia-Romagna, Italy. Human Vaccines and Immunotherapeutics, 2014, 10, 671-676.	3.3	8

#	ARTICLE	IF	CITATIONS
127	Lifelong vaccination as a key disease-prevention strategy. <i>Clinical Microbiology and Infection</i> , 2014, 20, 32-36.	6.0	24
128	Combined hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus- <i>Haemophilus influenzae</i> type b vaccine; Infanrix [®] , [®] hexa. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 129-137.	3.3	23
129	Hepatitis B: Are at-risk individuals vaccinated if screened and found negative for HBV? Results of an online survey conducted in six EU countries. <i>Vaccine</i> , 2014, 32, 6415-6420.	3.8	6
130	Surveillance of adverse events following immunization with meningococcal group C conjugate vaccine: Tuscany, 2005-2012. <i>Journal of Preventive Medicine and Hygiene</i> , 2014, 55, 145-51.	0.9	4
131	Primary Versus Secondary Failure After Varicella Vaccination. <i>Pediatric Infectious Disease Journal</i> , 2013, 32, e305-e313.	2.0	62
132	Economic evaluation of Varicella vaccination: results of a systematic review. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 1932-1942.	3.3	33
133	Cost-effectiveness of new adult pneumococcal vaccination strategies in Italy. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 699-706.	3.3	37
134	Economic analysis of the first 20 years of universal hepatitis B vaccination program in Italy. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 1119-1128.	3.3	28
135	Evaluation of bivalent human papillomavirus (HPV) vaccine safety and tolerability in a sample of 25 year old Tuscan women. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 1407-1412.	3.3	4
136	Sero-epidemiology of hepatitis B markers in the population of Tuscany, Central Italy, 20 years after the implementation of universal vaccination. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 636-641.	3.3	18
137	Progress in the elimination of measles and congenital rubella in Central Italy. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 649-656.	3.3	14
138	Predictive factors associated with the acceptance of pandemic and seasonal influenza vaccination in health care workers and students in Tuscany, Central Italy. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 2603-2612.	3.3	56
139	Varicella vaccination: results of a systematic review of economic evaluations. <i>European Journal of Public Health</i> , 2013, 23, .	0.3	0
140	Promoting physical activity in Florence (Italy): a health economic assessment of cycling to work and to school. <i>European Journal of Public Health</i> , 2013, 23, .	0.3	0
141	Progress towards measles and rubella elimination in Tuscany, Italy: the role of population seroepidemiological profile. <i>European Journal of Public Health</i> , 2012, 22, 133-139.	0.3	24
142	Impact on disease incidence of a routine universal and catch-up vaccination strategy against <i>Neisseria meningitidis</i> C in Tuscany, Italy. <i>Vaccine</i> , 2012, 30, 6396-6401.	3.8	11
143	Acellular pertussis vaccine use in risk groups (adolescents, pregnant women, newborns and health) Tj ETQq1 1 0.784314 rgBT /Overlock	3.8	48
144	Towards measles elimination in Italy: Monitoring herd immunity by Bayesian mixture modelling of serological data. <i>Epidemics</i> , 2012, 4, 124-131.	3.0	14

#	ARTICLE	IF	CITATIONS
145	Economic and clinical evaluation of a catch-up dose of 13-valent pneumococcal conjugate vaccine in children already immunized with three doses of the 7-valent vaccine in Italy. <i>Vaccine</i> , 2011, 29, 9521-9528.	3.8	17
146	Vaccine development. <i>Perspectives in Vaccinology</i> , 2011, 1, 115-150.	0.1	19
147	Safety and tolerability of bivalent HPV vaccine: An Italian post-licensure study. <i>Hum Vaccin</i> , 2011, 7, 136-146.	2.4	17
148	The prevention of infection-associated cancers. <i>Carcinogenesis</i> , 2011, 32, 787-795.	2.8	79
149	An overview on the implementation of HPV vaccination in Europe. <i>Hum Vaccin</i> , 2011, 7, 128-135.	2.4	43
150	Varicella vaccination in Europe – taking the practical approach. <i>BMC Medicine</i> , 2009, 7, 26.	5.5	123
151	Efficacy, duration of immunity and cross protection after HPV vaccination: A review of the evidence. <i>Vaccine</i> , 2009, 27, A46-A53.	3.8	76
152	Immunization with the 7-valent conjugate pneumococcal vaccine: Impact evaluation, continuing surveillance and future perspectives. <i>Vaccine</i> , 2009, 27, 3285-3290.	3.8	13
153	The expected impact of new vaccines and vaccination policies. <i>Zeitschrift Fur Gesundheitswissenschaften</i> , 2008, 16, 253-259.	1.6	12
154	Economic evaluation of varicella vaccination in Italian children and adolescents according to different intervention strategies: The burden of uncomplicated hospitalised cases. <i>Vaccine</i> , 2008, 26, 5619-5626.	3.8	28
155	Assessment of humoral and cell-mediated immunity against <i>Bordetella pertussis</i> in adolescent, adult, and senior subjects in Italy. <i>Epidemiology and Infection</i> , 2008, 136, 1576-1584.	2.1	16
156	Measurement and reporting of burden of disease for hepatitis A: results of the EUROHEP.NET feasibility survey. <i>European Journal of Public Health</i> , 2007, 17, 69-74.	0.3	4
157	Vaccination and Risk Groups: How Can We Really Protect the Weakest?. <i>Hum Vaccin</i> , 2007, 3, 217-219.	2.4	13
158	Progress in Italy in control and elimination of measles and congenital rubella. <i>Vaccine</i> , 2007, 25, 3105-3110.	3.8	22
159	Vaccination against hepatitis A in children: A review of the evidence. <i>Therapeutics and Clinical Risk Management</i> , 2007, 3, 1071-6.	2.0	10
160	Primary Hepatitis A vaccination failure is a rare although possible event: results of a retrospective study. <i>Vaccine</i> , 2006, 24, 6053-6057.	3.8	5
161	Travelers™ Compliance to Prophylactic Measures and Behavior During Stay Abroad: Results of a Retrospective Study of Subjects Returning to a Travel Medicine Center in Italy. <i>Journal of Travel Medicine</i> , 2006, 13, 338-344.	3.0	18
162	Measles outbreak in Grosseto, central Italy, 2006. , 2006, 11, E060803.4.		12

#	ARTICLE	IF	CITATIONS
163	Vaccination against hepatitis A during outbreaks starting in schools: what can we learn from experiences in central Italy?. <i>Vaccine</i> , 2005, 23, 2176-2180.	3.8	22
164	An economic evaluation of varicella vaccination in Italian adolescents. <i>Vaccine</i> , 2004, 22, 3546-3562.	3.8	38
165	Impact of universal vaccination programmes on the epidemiology of hepatitis B: 10 years of experience in Italy. <i>Vaccine</i> , 2003, 21, 685-691.	3.8	84
166	Perspectives of public health: present and foreseen impact of vaccination on the epidemiology of hepatitis B. <i>Journal of Hepatology</i> , 2003, 39, 224-229.	3.7	13
167	Hepatitis A booster vaccination: is there a need?. <i>Lancet, The</i> , 2003, 362, 1065-1071.	13.7	235
168	Vaccination against hepatitis B in health care workers. <i>Vaccine</i> , 2001, 19, 2389-2394.	3.8	57
169	Factors influencing vaccine uptake in Italy. <i>Vaccine</i> , 2001, 20, S8-S12.	3.8	43
170	Prevalence of hepatitis A virus infection in sewage plant workers of Central Italy: is indication for vaccination justified?. <i>Vaccine</i> , 2000, 19, 844-849.	3.8	19
171	Prevalence of diphtheria toxin antibodies in human sera from a cross-section of the Italian population. <i>Vaccine</i> , 1999, 17, 286-290.	3.8	12
172	Universal hepatitis B immunization: infant, and infant plus adolescent immunization. <i>Vaccine</i> , 1998, 16, S17-S22.	3.8	35
173	Success stories in the implementation of universal hepatitis B vaccination: an update on Italy. <i>Vaccine</i> , 1998, 16, S38-S42.	3.8	16
174	Experience of hepatitis A vaccination during an outbreak in a nursery school of Tuscany, Italy. <i>Epidemiology and Infection</i> , 1998, 121, 377-380.	2.1	41
175	Analytical and laboratory evaluation of a new fully-automated third generation enzyme immunoassay for the detection of antibodies to the hepatitis C virus. <i>Journal of Virological Methods</i> , 1996, 62, 113-122.	2.1	12
176	Implementation in Italy of a universal vaccination programme against hepatitis B. <i>Vaccine</i> , 1995, 13, S68-S71.	3.8	26
177	Implementation in Italy of a universal vaccination programme against hepatitis B. <i>Vaccine</i> , 1995, 13, S68-S71.	3.8	5